Pain in Guillain-Barré syndrome: A long-term follow-up study

Neurology

Volumn 75, Issue 16, 2010, Pages 1439-1447

  Ruts, L ^a   Drenthen, J ^a   Jongen, J L M ^a   Hop, W C J ^a   Visser, G H ^a   Jacobs, B C ^a   Van Doorn, P A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; DISABILITY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GUILLAIN BARRE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SENSORY DYSFUNCTION; SENSORY NERVE; SEROLOGY; ACTION POTENTIAL; BLOOD; CHI SQUARE DISTRIBUTION; ELECTROMYOGRAPHY; FATIGUE; HOSPITALIZATION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; REACTION TIME; RETROSPECTIVE STUDY; STATISTICS; TIME;

ANTIBODY; GANGLIOSIDE;

ACTION POTENTIALS; ADULT; ANTIBODIES; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DISABILITY EVALUATION; ELECTROMYOGRAPHY; FATIGUE; FEMALE; GANGLIOSIDES; GUILLAIN-BARRE SYNDROME; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; QUESTIONNAIRES; REACTION TIME; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TIME FACTORS;

EID: 78049491382     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181f88345     Document Type: Article

References (40)

1. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008;7:939-950.
2. Pentland B, Donald SM. Pain in the Guillain-Barré syndrome: a clinical review. Pain 1994;59:159-164.
3. Andersson T, Siden A. A clinical study of the Guillain-Barré Syndrome. Acta Neurol Scand 1982;66:316-327.
4. Forsberg A, Press R, Einarsson U, Pedro-Cuesta J, Widen HL. Impairment in Guillain-Barré syndrome during the first 2 years after onset: a prospective study. J Neurol Sci 2004;227:131-138.
5. Gorson KC, Ropper AH, Muriello MA, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology 1996;47:813-817.
6. Greenwood RJ, Newsom-Davis J, Hughes RA, et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;1:877-879.
7. Korinthenberg R, Schessl J, Kirschner J. Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study. Neuropediatrics 2007;38:10-17.
8. Moulin DE, Hagen N, Feasby TE, Amireh R, Hahn A. Pain in Guillain-Barré syndrome. Neurology 1997;48:328-331.
9. Ropper AH, Shahani BT. Pain in Guillain-Barré syndrome. Arch Neurol 1984;41:511-514.
10. Ruts L, van Koningsveld R, Jacobs BC, van Doorn PA. Determination of pain and response to methylprednisolone in Guillain-Barré syndrome. J Neurol 2007;254:1318-1322.
11. Winer JB, Hughes RA, Osmond C. A prospective study of acute idiopathic neuropathy: I: clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988;51:605-612.
12. Green DM, Ropper AH. Mild Guillain-Barré syndrome. Arch Neurol 2001;58:1098-1101.
13. Koga M, Yuki N, Hirata K. Pain in Miller Fisher syndrome. J Neurol 2000;247:720-721.
14. Ruts L, Rico R, van Koningsveld R, et al. Pain accompanies pure motor Guillain-Barré syndrome. J Peripher Nerv Syst 2008;13:305-306.
15. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27: suppl: S21-S24.
16. Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992;326:1130-1136.
17. McMahon SB en Koltzenburg M. Wall and Melzack's Textbook of Pain, 5th ed. London: Elsevier Health Sciences; 2009.
18. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975;1:277-299.
19. van der Kloot WA, Oostendorp RA, van der Meij J, van den Heuvel J. The Dutch version of the McGill pain questionnaire: a reliable pain questionnaire. Ned Tijdschr Geneeskd 1995;139:669-673.
20. Paul SM, Zelman DC, Smith M, Miaskowski C. Categorizing the severity of cancer pain: further exploration of the establishment of cutpoints. Pain 2005;113:37-44.
21. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61:277-284.
22. Kleyweg RP, Van Der Meché FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14:1103-1109.
23. Merkies IS, Schmitz PI, van der Meché FG, van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies: Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 2000;54:943-949.
24. Merkies IS, Schmitz PI, van der Meché FG, van Doorn PA. Comparison between impairment and disability scales in immune-mediated polyneuropathies. Muscle Nerve 2003;28:93-100.
25. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2:750-753.
26. Sharrack B, Hughes RA. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 1999;5:223-233.
27. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale: Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123.
28. Merkies IS, Schmitz PI, Samijn JP, van der Meché FG, Van Doorn PA. Fatigue in immune-mediated polyneuropathies: European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 1999;53:1648-1654.
29. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-140.
30. Jacobs BC, van Doorn PA, Schmitz PI, et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol 1996;40:181-187.
31. Ang CW, Jacobs BC, Brandenburg AH, et al. Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barré syndrome. Neurology 2000;54:1453-1458.
32. Kuijf ML, van Doorn PA, Tio-Gillen AP, et al. Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci 2005;239:37-44.
33. Buschbacher RM. Manual of Nerve Conduction Studies, 2nd ed. New York: Demos Medical Publishing; 2006.
34. Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome: Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998;44:780-788.
35. Ruts L, van Koningsveld R, van Doorn PA. Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations. Neurology 2005;65:138-140.
36. Rekand T, Gramstad A, Vedeler CA. Fatigue, pain and muscle weakness are frequent after Guillain-Barré syndrome and poliomyelitis. J Neurol 2009;256:349-354.
37. Bernsen RA, Jager AE, Schmitz PI, van der Meché FG. Long-term sensory deficit after Guillain-Barré syndrome. J Neurol 2001;248:483-486.
38. Pan CL, Tseng TJ, Lin YH, Chiang MC, Lin WM, Hsieh ST. Cutaneous innervation in Guillain-Barré syndrome: pathology and clinical correlations. Brain 2003;126:386-397.
39. Kabore R, Magy L, Boukhris S, Mabrouk T, Lacoste M, Vallat JM. Contribution of corticosteroid to the treatment of pain in the acute phase of Guillain-Barré syndrome. Rev Neurol 2004;160:821-823.
40. Sánchez-Guerra M, Infante J, Pascual J, Berciano J. Severe backache in Guillain-Barré syndrome. Muscle Nerve 2002;25:468.